EP Patent

EP0522001B1 — Supportive use of linomide (r)

Assigned to Pfizer Health AB · Expires 1996-06-26 · 30y expired

What this patent protects

The present invention concerns the use of Linomide, i.e. N-phenyl-N-methyl-1,2-dihydro-4-hydroxy-1-methyl-2-oxo-quinoline-3-car boxamide for the treatment of humans subjected to BMT, cytostatic treatment irradiations or combinations thereof.

USPTO Abstract

The present invention concerns the use of Linomide, i.e. N-phenyl-N-methyl-1,2-dihydro-4-hydroxy-1-methyl-2-oxo-quinoline-3-car boxamide for the treatment of humans subjected to BMT, cytostatic treatment irradiations or combinations thereof.

Drugs covered by this patent

Patent Metadata

Patent number
EP0522001B1
Jurisdiction
EP
Classification
—
Expires
1996-06-26
Drug substance claim
No
Drug product claim
No
Assignee
Pfizer Health AB
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.